AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05569785 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise Therapy
Description: 4 weeks of Resistance Exercise Therapy. This is a 4 week resistance exercise training programme that can be completed at home. The programme is designed to be progressive. It was designed by a bariatric physiotherapist and an exercise physiologist. This exercise programme will be discussed at the screening visit, educational material will be provided to the participants who are randomised to the intervention RET group.~Safety advice will be given to each eligible participant to ensure that if they feel unwell, develop chest pain/tightness, then they must seek advice from GP/urgent care if necessary. The exercises will need to be performed at least three times a week. Compliance will be monitored with Fitbit downloads at each visit. Fitbits will be worn during exercise sessions only.
Study NCT05279417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-450 50 mg oral tablet BID
Description: Oral, small molecule MK2 inhibitor
Study NCT05279417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablet manufactured to match ATI-450 in appearance
Study NCT05279417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 15 mg to 25 mg weekly
Study NCT05279417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 15 mg to 25 mg weekly
Study NCT05279417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-450 20 mg oral tablet BID
Description: Oral, small molecule MK2 inhibitor
Study NCT05619445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Liquid Egg
Description: Subjects will consume 2 fluid ounces of whole liquid eggs per day for 120 days.
Study NCT05619445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based Egg Substitute
Description: Subjects will consume 2 fluid ounces of liquid plant-based egg substitute (JUST eggs) per day for 120 days.
Study NCT06102824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: 1.4mg/m2, IV, days 1 and 8, q3w
Study NCT06102824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthracycline
Description: Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w
Study NCT06102824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6, IV, q3w or q4w OR Carboplatin AUC 2+Gemcitabine 1000mg/m2, IV, days 1 and 8, q3w OR Carboplatin AUC 2+Albumin-bound paclitaxel 125mg/m2, IV, days 1 and 8, q3w
Study NCT06102824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Utidelone
Description: 30mg/m2, IV, once per day on days 1-5, q3w
Study NCT06102824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab deruxtecan
Description: 5.4mg/kg, IV, q3w
Study NCT06102824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacituzumab govitecan
Description: 10mg/kg, IV, days 1 and 8, q3w
Study NCT05875623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MALPIP criteria
Description: In the intervention group, the clinical pharmacist will apply the MALPIP criteria on all the admission and discharge medications. The intervention will consist of 4 steps: i) pharmacist review using MALPIP criteria to detect PIM, ii) discussion with doctors for deprescribing decision iii) discussion with patients and documentation of shared decision iv) follow up patients
Study NCT06395389 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HealthEdu)
Description: The Health Education condition is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session focuses on providing in-depth information on good sleep hygiene and habits to improve sleep and information on positive eating habits, nutrition, and physical activity/functional exercise. The second session focuses on providing information about stress and social connection.
Study NCT06395389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values in Action (VIA)
Description: VIA is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session encourages participants to ask themselves what is important to them. This discussion emphasizes identifying values and ways to live in line with their values, as well as why they use cannabis and providing personalized feedback related to their reasons for use. The second session asks participants to reflect on information from session one and consider what they would like to do next to live in line with their values.
Study NCT05951959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Investigational Product
Study NCT05951959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Investigator Product
Study NCT05951959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Investigator Product
Study NCT06566755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab (AK104) combined with chemotherapy and bevacizumab
Description: Participants receive Cadonilimab PLUS chemotherapy and bevacizumab of each 21-day cycle.~Treatment period (4-8 cycles)：~* Cadonilimab: 10mg/kg, intravenous infusion, D1, Q3W;~* CapeOx chemotherapy regimen Q3W+ bevacizumab, Q3W:~oxaliplatin: 130 mg/m2 intravenous infusion, D1, Q3W; capecitabine: 850 mg/m2 orally, D1-14, Q3W, twice daily; bevacizumab injection: 7.5mg/kg, IV, D1, Q3W. Maintenance treatment period：~* Cadonilimab: 10mg/kg, administered D1, Q3W;~* capecitabine: 1000 mg/m2 orally, D1-14, Q3W, twice daily;~* bevacizumab injection: 7.5mg/kg, IV, D1, Q3W.
Study NCT06640023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Intervention
Description: For new orders of oral Z-drugs tablets (zolpidem, zolpidem CR, zaleplon, and eszopiclone), the EHR dispense quantity default will be changed to 10 pills with 0 refills for all dosage levels. Dispense quantities for Z-drug reorders and renewals will not be changed.
Study NCT06165003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of broselow tape
Description: In the research, the nurse is the decision maker in the selection of the catheters to be used in the procedures (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion) for the patients in the control group.~In these procedures, the nurse's choices will be evaluated as control group data as routine clinical practice.~After the control group data is collected, Broselow tape will be used in the selection of catheters to be used in the procedures to be performed on the patients in the experimental group (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion).~Our research will be conducted to examine the effect of nurses' use of Broselow tape in non-resuscitation applications and to minimize errors and application disruptions in procedures involving nurses.
Study NCT06640023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accountable Justification
Description: For qualifying Z-drug orders, an EHR alert will suggest removing the Z-drug, adding a CBT-I referral, or both. If the alert recommendation is not followed, clinicians will be asked to provide a justification for their decision when the order is signed. The justification will display in the After Visit Summary.~The alert suggestion depends on the recent history of Z-drug prescriptions for a given patient. When a Z-drug is being ordered for patients with 180 days supply of Z-drugs or fewer in the last 365 days, the alert will prompt removal of the Z-drug and addition of a CBT-I referral to the order. When a Z-drug is being ordered for patients with 181 days supply of Z-drugs or more in the last 365 days, the alert will only prompt addition of a CBT-I referral to the order.~If a CBT-I referral is already in the current order or has been ordered for a patient in the past 180 days, the alert to add a CBT-I referral to the order will not display.
Study NCT05130567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-128 capsules
Description: Oral dosing with LP-128 capsules
Study NCT05130567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Oral dosing with placebo capsules to match LP-128 capsules.
Study NCT05387759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant Supratherapeutic Dose
Description: Aticaprant supratherapeutic dose capsule will be administered orally.
Study NCT05387759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant Therapeutic Dose
Description: Aticaprant therapeutic dose capsule will be administered orally.
Study NCT05387759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.
Study NCT05387759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin capsule will be administered orally.
Study NCT04705077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR419
Description: 2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.
Study NCT05460624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg-containing breakfast
Description: Involves participants eating six premade egg-containing breakfast meals per week for 12 weeks. Each meal contains 2 eggs to provide 12 eggs per week.
Study NCT05460624 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Typical American-style breakfast excluding eggs
Description: Involves participants eating six premade egg-excluding breakfast meals per week for 12 weeks. Breakfast meals are matched to the intervention egg-containing breakfast meals on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
Study NCT05393310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post isometric relaxation
Description: The therapist will apply Post isometric relaxation ensure that foot will not actually move and only a static muscle contraction apply and held for 20 seconds. This will be followed by 2-3 second of relaxation, and then the foot passively stretched to dorsiflexion up to the palpated barrier and/or tolerance to stretch. This will continue until no further gains achieved 2 sets of 5 repetitions a day for 3 days a week for 4 weeks
Study NCT05393310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MWM group
Description: MWM group will receive inferior tibiofibular, talocrural, or cubometatarsal MWM 2-8 treatment sessions over 4 weeks.
Study NCT05389592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active tDCS and cognitive training
Description: Electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strenght is set at 2mA for 20 minutes, daily for 5 continuous days (with a 2-day pause) for 4 weeks. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
Study NCT05389592 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS and cognitive training
Description: Sham electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining session time. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
Study NCT05676242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablet
Description: Orally administered, twice a day
Study NCT05676242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jaktinib Hydrochloride Tablet
Description: Orally administered, twice a day
Study NCT04805905 — intervention group
Intervention type: OTHER
Intervention: FACE-Q patient reported outcome
Description: As both interventions of treatment are gold standards and clinical equipoise exists if one intervention is superior to the other, there is no true control group. However, for the purpose of the application, the local flap group will be chosen as the control group.~Skin graft (Experimental): Participants in the experimental group will receive a skin graft and receive the FACE-Q skin cancer questionnaire pre- and post-treatment. There will also be photos taken of the patient's face along with the distributed questionnaires.~Local flap (Control): Participants in the experimental group will receive a local flap and receive the FACE-Q questionnaire pre- and post-treatment.
Study NCT06532903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selective muscle electrostimulation with exponential current
Description: An electroevaluation will be performed, with an exponential current generator equipment, using Meditea® brand Neuromatic 700 equipment, which consists of a first application of the current, the pulse width (in milliseconds) in which a contraction is achieved will be sought. frank, visible and selective of the facial muscle that is being stimulated. The purpose is to identify the pulse width and the lowest intensity to obtain a frank, visible and selective contraction, understood as the best quality.
Study NCT06532903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial muscle reeducation in front of the mirror
Description: Muscle re-education: Symmetrical facial movements will be requested, activating the muscles of the affected side, avoiding the participation of the unaffected side. We will work with the patient sitting in front of a mirror, asking him to perform the following actions or gestures: raise his eyebrows, frown, close his eyes (tightly and blink), smell an unpleasant odor, show his fangs, blow a kiss, blow , fake smile (lip corner pulled back horizontally), frank smile (lip corner pulled back and up, showing teeth), kiss and pout. The functional capacity of the mouth will be trained, inflating the cheekbones and moving the air from one side to the other, avoiding compensations. Depending on the degree of facial dysfunction and its condition, the kinesiologist will perform a stretch reflex, facilitation of movement and/or inhibition of it. Three series of five repetitions of each gesture described will be done.
Study NCT04879303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted social skill intervention
Description: Social robotics will be used by the instructor to teach social skills to the children with ASD for 12 weekly sessions.
Study NCT04879303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Human-only instruction programme on social skill training
Description: The children will receive only the human-delivered training throughout the 12 sessions, with the content and sequence of activities the same as the robotic intervention group.
Study NCT04868201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0-anxiety
Description: 0-anxiety is a self-guided app-based utilizing virtual reality establish in cognitive behavior therapy treatment.
Study NCT05257265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine Hydrochloride
Description: Capsule
Study NCT05257265 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study NCT05673720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS paired with active MBM
Description: Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session for 5 times via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session for 5 times by a recorded meditation.
Study NCT05673720 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS paired with sham MBM
Description: For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
Study NCT04901884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/MR with 18F-FDG
Description: (18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.
Study NCT04856696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PGT-A
Description: trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform
Study NCT04856696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PGT-A
Description: trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform
Study NCT04856696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: non-invasive PGT-A
Description: cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform
Study NCT04740606 — intervention group
Intervention type: DEVICE
Intervention: Augmented Reality Navigation System
Description: Investigators will assess the nodules based on the CT images of subjects before procedure. And then, the appropriate intra-airway path planned by the Augmented Reality Navigation System will be selected. The bronchoscopy with intra-airway navigation under the guidance of the Augmented Reality Navigation System will be performed and the following surgical information will be record.
Study NCT05813054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HA matrix ingredient
Description: 1 capsule/day
Study NCT05813054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule/day
Study NCT06572176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: With fluorescent concretization group
Description: Nurses were given the fluorescent lotion and asked to apply it all over their hands. The CE-certified test lotion is in gel form and is safety-approved. The lotion disperses particles the same size as bacteria on the skin. These particles settle on the skin, similar to the behavior of microorganisms, but disappear with hand washing under the influence of fluorescent light. They were then asked to wash their hands with 4 ml of soap. Two researchers marked the hand washing steps independently using the Hand Washing Skill Checklist. The duration of hand washing was recorded with a mobile stopwatch for each participant. Hand washing efficiency was evaluated using the Derma Litecheck device. UV rays were used after using the test lotion and drying the hands. Since any fluorescent material left on the hands would shine under UV light, it was possible to judge how well the hands were cleansed. The dirty spots were shown to the participants, and the reason for this was discussed.
Study NCT06160024 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Program to improve data quality of national quality indicators
Description: Interventions will be developed based on the findings from the first data collection period.~A bundle of interventions (Program to improve data quality of national quality indicators) will be offered to participating long-term care facilities to support changing behavior in data collection procedures via training and supporting material as implementation strategies with the goal to improve the data quality of the national quality indicators. The program will be tested in a separate pilot study. The second data collection period in the current study will be used to evaluate the effect of the implemented program.
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: Blood will be collected from a catheter (IV) that is already in place or using a needle stick into a vein.~Blood will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort).
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: Urine Collection
Description: Urine will be collected through a urinary catheter that is already in place or by urinating into a cup.~Urine will be collected in hospital only (Cohorts A, B)
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: Nasal, oral, and rectal swabs
Description: Nasal, oral, and rectal swabs inserted into the nose, mouth, and rectum, respectively. The swabs will be rubbed inside the cavity and then removed the swab.~Oral and nasal swabs will also be collected in hospital (Cohort A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort). Rectal swabs will be collected in hospital only (Cohorts A, B).
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: Stool collection
Description: Stool will be collected either in a cup after defecation or by collecting it from a tube or bag that may already be in place that is catching stool.~Stool will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization (Long Term Outcomes Cohort).
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: Heat Moisture Exchange Filter collection
Description: An HME filter is a sponge that is placed in the tubing between a patient and breathing machine. It reduces the amount of heat and moisture a patient loses when on a breathing machine. Moisture from breath is collected in this filter. The filter is changed every few hours. When the filter is changed, it will be saved to collect the moisture that it contains and run tests on it.~HME filters will be collected in hospital on intubated patients only (Cohorts A, B).